Corporate Banner
Satellite Banner
Technology Networks Header
Saturday, November 29, 2014
 
Register | Sign in
Home Page > Videos > Not happy with your ion chromatograph? Switch to Metrohm now and save!
  Videos

Return

Not happy with your ion chromatograph? Switch to Metrohm now and save!
Metrohm AG

Anyone thinking about exchanging his existing IC system should not wait any longer and switch to Metrohm now. Less need for expensive consumables, outstanding warranties and integral, fully automated sample preparation will benefit users with lower running costs, more efficiency, and highly dependable Swiss technology - for routine analysis and research alike. Investing in Metrohm ion chromatography means routine analysis with much less of expensive consumables such as syringe filters and filter caps required. Integral, fully automated sample preparation (inline dilution, inline calibration, inline dialysis) saves time and stress. The most important benefit in terms of saving money is the patented Metrohm anion suppressor module (MSM). Many users of ion chromatography may have grown used to costly replacements of the anion suppressor of their system every six months or even more frequently, not knowing that Metrohm ion chromatographs come with a 10 year suppressor warranty. This feature alone counts for thousands of US dollars saved over the lifetime of any Metrohm IC system. More and equally exclusive warranties such as a 10 year spare part warranty, 5 year software support, and a general 3 year instrument warranty contribute to a package that make Metrohm ion chromatography the better deal.

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Gene Therapy Provides Safe, Long-Term Relief for Patients with Severe Hemophilia B
Gene therapy pioneered by St. Jude Children’s Research Hospital, University College London and the Royal Free Hospital provides men with hemophilia B reliable relief from the bleeding disorder.
Protein Predicts Response To New Immunotherapy Drug
Trial shows that response to treatment may be predicted by the presence of an immune-suppressing protein in non-cancerous immune cells.
NIAID/GSK Experimental Ebola Vaccine Appears Safe, Prompts Immune Response
Results from NIH Phase 1 clinical trial support accelerated development of candidate vaccine.
Researchers Develop Efficient Method to Produce Nanoporous Metals
New technique to manufacture nanoporous metals is cheap and can be done over many scales.
Turkeys may be Lifesavers
Antibiotic to target staph infections, strep, comes from good bacteria in turkeys.
A Hybrid Vehicle That Delivers DNA
University at Buffalo researchers are developing new technology to improve DNA vaccines. The new transport system for DNA vaccines could help treat HIV, malaria, HPV and other major illnesses.
Big Data Set To Make A Big Difference In Childhood Cancer Treatment
UTS researchers are working with the Kids Research Institute to visualise large quantities of patient data to better diagnose and treat childhood cancer patients.
Two Studies Identify A Detectable, Pre-Cancerous State In The Blood
Findings pave way for new lines of cancer research focused on detection and prevention.
A Link between DNA Transcription and Disease-Causing Expansions Which Lead to Hereditary Disorders
A Tufts University study explores the relationship between transcription and the expansions of DNA repeats.
Did You Hear The One About The Two Businessmen On A Plane?
EquipNet’s vision ‘to revolutionize the way companies manage their surplus assets’ was first conceived at 30,000 feet somewhere between Chicago and Boston in 1999. Here we learn more about the company's first 15 years.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv